Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03362606
PHASE1/PHASE2

Engineered Immune Effectors Against Ovarian Cancer

Sponsor: Shenzhen Geno-Immune Medical Institute

View on ClinicalTrials.gov

Summary

This is a single-arm, open-label, phase I/II trial to evaluate the safety and efficacy of ovarian cancer specific cytotoxic lymphocytes (OC-CTLs) in women.

Official title: Intervention of Ovarian Cancer Based on Engineered Immune Effectors (EIEs)

Key Details

Gender

FEMALE

Age Range

10 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2026-06-01

Completion Date

2030-12-31

Last Updated

2026-06-23

Healthy Volunteers

No

Conditions

Interventions

BIOLOGICAL

OC-CTLs

2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, abdominal cavity or tumor injection each time

Locations (1)

Shenzhen Geno-immune Medical Institute

Shenzhen, Guangdong, China